Choose a country to view content specific to your location

AssayProven™ Immunoassay Reagents for Faster IVD Assay Development

Start stronger. Screen less. Optimize faster.

A Stronger Starting Point for Assay Development

Developing an IVD immunoassay can require screening large numbers of antibodies and antigens, troubleshooting incompatible combinations, and generating performance data before your team can confidently move into assay optimization.
AssayProven™ gives IVD immunoassay developers a stronger starting point. Every AssayProven™ curated reagent is:
  • Supported by extensive performance data.
  • Comprehensively characterized.
  • Tested in a commercially relevant assay format.
  • Part of a validated matched antibody pair.
  • Rigorously screened and selected from our extensive network.
Close-up of an analog clock with a purple-tinged face and black hands under neon lighting.

Reduce Troubleshooting and Rework

Recommended combinations and defined performance information can help identify compatibility and performance considerations earlier.
Close-up illustration of orange antibodies binding to blue virus particles in a laboratory-like scene.

Speed Reagent Selection

Extensive comparative screening helps narrow the field to stronger-performing candidates before evaluation begins.

Row of clear test tubes with colored liquids in a metal rack, arranged from red to purple.

Build with Greater Confidence

Format-relevant performance information and technical documentation give teams more information to evaluate before design lock and scale-up.
Researchers in a lab analyzing data on computer monitors, with one pointing at the screen while two colleagues observe

Development Time Saved

AssayProven™ may help reduce early feasibility and design work by shortening screening, troubleshooting, and rework by up to 25%-50%.

Infographic comparing traditional vs. AssayProven development timelines: traditional 9–12 months total with Reagent Screening (3–6 mo) and Optimization (6–12 mo); AssayProven shows 3–6 months total with Curated Selection (1–2 mo) and Optimization (3–6 mo), saving ~6 months.

What is AssayProven™

AssayProven™ is a curated portfolio of antibodies and antigens organized around selected assay component combinations and supported by product-specific characterization information for IVD assay development.
A Curated Component Approach

Rather than presenting antibodies and antigens only as individual products, AssayProven™ brings selected reagents together in recommended combinations for specific targets and applications.

Product-Specific Performance Information
Supporting information varies by product and assay format. It may include sensitivity, specificity, cross-reactivity, affinity, correlation, and other characterization results generated in CLIA, FIA, or lateral flow studies.
Learn more about AssayProven™.

Benefits

  • Selected assay component combinations
  • Product-specific characterization data
  • Relevant assay-format context
  • Supporting technical information

Featured AssayProven™ Reagents

Explore AssayProven™ reagents across infectious disease, TORCH, tropical disease, cardiac, thyroid, allergy, and neurological disease applications. Product-specific performance information and documentation vary by reagent.

Application Assay Target Target Type Tested Assay Format* Recommended catalog pair Performance Evaluation Material
Neurological disease markers GFAP Antigen CLIA AXGFA01RAB*
AXGFA02RAB*
Human serum, EDTA plasma, and GFAP reference materials
Neurological disease markers Amyloid beta 1–42 Antigen CLIA AXAMY01RAB*
AXAMY02RAB*
K2-EDTA plasma, reference materials, and antigen-spiked plasma
Neurological disease markers Amyloid beta 1–40 Antigen CLIA AXAMY02RAB*
AXAMY03RAB*
Human K2-EDTA plasma and Aβ1–40 reference materials
Neurological disease markers ApoE4 Antigen CLIA AXAPO01RAB*
AXAPO02RAB*
EDTA plasma of known APOE genotype and ApoE4 reference materials
Neurological disease markers NfL Antigen CLIA AXNFL01RAB*
AXNFL02RAB*
Human serum, EDTA plasma, and NfL reference materials
Neurological disease markers p-Tau181 / total Tau Antigen CLIA AXT1801RAB*
AXT2102RAB*
p-Tau181 reference materials and EDTA plasma specimens, including specimens classified by amyloid-PET status †
Neurological disease markers p-Tau217 / total Tau Antigen CLIA AXT2101RAB*
AXT2102RAB*
p-Tau217 reference materials and EDTA plasma specimens, including specimens classified by amyloid-PET status
Infectious Disease (TB) Human IFN-γ Antigen CLIA AXIFN01MAB
AXIFN02RAB
Clinical samples
Infectious Disease Influenza A Antigen LFA AXIFA01RAB
AXIFA02RAB
Recombinant Influenza A nucleoprotein
Infectious Disease Influenza B Antigen LFA AXIFB02RAB
AXIFB01MAB
Recombinant Influenza B nucleoprotein
Infectious Disease SARS-CoV-2 NP Antigen LFA AXSAR01MAB
AXSAR02MAB
Recombinant SARS-CoV-2 nucleoprotein
TORCH Toxoplasma gondii IgG Antibody CLIA AXTOX01RAG
AXIGG01MAB
Clinical serum samples
TORCH Rubella IgG Antibody CLIA AXRUB01RAG
AXIGG01MAB
Clinical serum samples
Tropical Diseases Dengue NS1 Antigen LFA AXDEN02MAB
AXDEN01PAB
Viral culture supernatants
Cardiac Markers D-dimer Antigen FIA AXDDI02RAB
AXDDI01RAB
Clinical plasma samples
Thyroid TSH Antigen FIA AXTSH01RAB
AXTSH02RAB
Clinical serum and whole blood samples
Allergy Total IgE Antigen FIA AXIGE01RAB
AXIGE02RAB
Clinical serum samples

*AssayProven Neuromarkers are not available for sale in China, India, Japan, South Korea, Russia, the Middle East, or Africa. Product availability may vary by country and may be subject to local regulatory requirements.
How can verified reagents reduce upfront screening and provide a stronger start to early assay development?

Explore the AssayProven™ flyer to see how curated reagent combinations and supporting performance data can help streamline feasibility and design—and view the available product portfolio.

FAQS

What makes AssayProven™ different from other matched antibody pairs or catalog reagents?

AssayProven™ brings together recommended reagent combinations selected through extensive candidate screening, testing in a relevant assay format, and comprehensive product-specific characterization. Meridian draws on its global development resources, manufacturing expertise, and strategic partnerships to evaluate antibody and antigen candidates and identify promising pairs. 

Depending on the pair, supporting information may include sensitivity, specificity, cross-reactivity, affinity, correlation, and details of the materials and conditions used in testing. This gives IVD developers evidence beyond a catalog description or pairing recommendation, helping them choose a more informed starting point for evaluation in their own assay. 

Yes. AssayProven™ provides screened components and supporting information to help you begin feasibility work. Your team still needs to assess the pair in its intended assay format, instrument, and sample matrix, then complete the optimization and validation appropriate for the finished assay.

Contact Meridian Life Science’s technical team to discuss your target, intended assay format, and performance requirements. They can help you explore relevant antibodies or antigens in Meridian’s broader portfolio and discuss available options for your development program. 

Matched antibody pairs are capture and detection antibodies selected because they can work together to recognize the same target. In a sandwich immunoassay, the antibodies generally need to recognize different sites on the analyte so capture and detection can occur in the same assay. AssayProven™ provides recommended components selected through comparative screening together with relevant performance information. 

NCBI Assay Guidance Manual – Immunoassay Methods

The best capture/detection orientation cannot always be predicted from the performance of individual antibodies. Pair combinations are typically evaluated experimentally for signal, background, sensitivity, specificity, and compatibility. AssayProven™ is designed to provide a more focused starting point by offering recommended combinations that have already undergone comparative evaluation. 

NCBI Assay Guidance Manual – Immunoassay Methods

Antibody pair screening evaluates combinations of candidate capture and detection antibodies to identify pairs that provide suitable signal separation and analytical performance. It helps determine which combinations are most promising before broader assay optimization begins.

Antibody performance can be influenced by assay architecture, sample matrix, labeling chemistry, membranes or surfaces, incubation conditions, and other variables. Product-specific format and evaluation information can therefore help developers judge potential fit earlier in development.

NCBI Assay Guidance Manual – Immunoassay Methods

Depending on the target and assay, useful evaluation information can include analytical sensitivity, specificity, cross-reactivity, correlation with an established method, affinity, sample matrix, and assay-format performance. The exact AssayProven™ data package varies by product. 

No. Recommended or pre-qualified pairs can reduce the breadth of initial reagent screening and provide useful development information, but developers must still optimize and confirm performance in their own assay configuration, platform, sample matrix, intended-use population, and acceptance criteria. 

Yes. The initial AssayProven™ portfolio includes products evaluated in lateral flow assay (LFA), fluorescence immunoassay (FIA), and chemiluminescent immunoassay (CLIA) formats. The supported format is product-specific (not in all formats) and should be confirmed in the associated technical documentation. 

Even after a suitable antibody pair has been selected, sample-related interference and non-specific binding can affect assay performance. Immunoassay blockers can be evaluated during optimization to help address interference from HAMA, heterophilic antibodies, rheumatoid factor, and related sources.

Get in Touch With Us